<DOC>
	<DOCNO>NCT00060385</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat non-Hodgkin 's lymphoma . PURPOSE : Randomized phase II/III trial compare effectiveness combination chemotherapy without etoposide treat old patient non-Hodgkin 's lymphoma previously treat .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Etoposide Treating Older Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare complete response rate older patient diffuse large B-cell peripheral T-cell non-Hodgkin 's lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) v without etoposide . - Compare overall survival patient treat regimen . - Compare time treatment failure patient treat regimen . - Compare freedom progression patient treat regimen . - Determine toxicity CHOP plus etoposide patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord cellular type ( B-cell v T-cell ) , initial stage disease ( I II v III IV ) , WHO performance status ( 0-1 v 2 ) , lactic dehydrogenase level ( LDH ) ( normal v abnormal ) . Patients randomize 1 2 treatment arm . - Arm I ( CHOP chemotherapy ) : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 . Patients also receive oral prednisone day 1-5 . Treatment repeat every 21 day 3 course absence unacceptable toxicity . Patients undergo disease evaluation . Patients disease progression change disease remove study . Patients responsive stage I II disease receive 1 additional course demonstrate 3 follow condition ( baseline ) : LDH elevation , WHO performance status 0-1 , great single diameter tumor site le 5 cm . Patients responsive stage I II disease receive 3 additional course demonstrate 1 follow condition ( baseline ) : LDH elevation , WHO performance status 2 , and/or great single diameter tumor site least 5 cm . Patients responsive stage III IV disease receive 3 additional course . After completion chemotherapy , patient responsive stage I II disease undergo involved field radiotherapy daily 5 day week 3.5-4 week . Patients initial bulky stage III IV disease may also undergo radiotherapy . - Arm II ( CHOP chemotherapy etoposide ) : Patients receive CHOP chemotherapy arm I plus oral etoposide 2 3 time daily day 1-10 . Treatment repeat every 21 day 3 course absence unacceptable toxicity . Patients receive additional course arm I . After completion chemotherapy , patient responsive stage I II disease initial bulky stage III IV disease undergo radiotherapy arm I . Quality life assess baseline , course 3 , end chemotherapy , every 6 month 3 year , annually thereafter . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 686 patient ( 126 phase II 560 phase III ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large Bcell* peripheral Tcell nonHodgkin 's lymphoma REAL/WHO classification , include follow : All morphological clinical variant All Ann Arbor stage NOTE : *Presence small cell , indolent lymphoma component bone marrow biopsy allow No Burkittlike lymphoma Previously untreated disease No cerebral meningeal involvement At least 1 measurable target lesion least 1.1 cm Cheson criterion PATIENT CHARACTERISTICS : Age 70 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 ( unless relate bone marrow infiltration ) Hepatic Bilirubin le 1.8 mg/dL* AST ALT less 2.5 time upper limit normal ( ULN ) * Alkaline phosphatase less 4 time ULN* NOTE : *Values threshold allow related nonHodgkin 's lymphoma Renal Creatinine clearance least 50 mL/min Cardiovascular LVEF least 50 % Other HIV negative No history concurrent severe disease would preclude study treatment No prior concurrent malignancy except adequately treat basal cell skin cancer , curatively treat carcinoma situ cervix , curatively treat solid malignancy evidence disease least 5 year prior study entry No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent participation another investigational drug study No concurrent antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>